

Prevalence of Non Fermenting Gram Negative Bacilli with Their in vitro Antibiotic Sensitivity Profile in RIMS, Ranchi

Ashok Kumar Sharma¹, A. Aparajita^{2*}, Manoj Kumar³, Amber Prasad⁴

¹Associate Professor, ²Junior Resident, ³Professor & HOD, ⁴Assistant Professor

Department of Microbiology, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India.

ABSTRACT

Background: Non fermenting Gram Negative Bacilli are diverse and complex group of bacteria that possess very few defined characteristics. They are aerobic, non-fermenting Gram negative bacilli which were initially considered as contaminants but have come up with life threatening infections in hospitals as multidrug resistant organisms posing a threat because of their inherent and acquired drug resistance nature.

Aims: Isolation and identification of NFGNB in clinical samples and determination of their antibiotic sensitivity profile.

Materials and Methods: The study was conducted in the Department of Microbiology, RIMS, Ranchi from February 2017-July 2017. Various clinical samples reaching the Bacteriology section of the Department of Microbiology were processed and NFGNB were isolated and identified using standard procedure and their antibiotic susceptibility was performed.

Results: A total of 3581 samples were received out of which 2246 were culture positive and 217 were identified as NFGNB. The isolation rate of NFGNB was 9.6%. Number of males affected by NFGNB was 121 and that of females was 96. Analysed by specimen NFGNB were isolated from 91 urine, 74 pus, 11 ear swab, 6 sputum, 8 body fluid, 21 blood culture and 6 catheter tip samples. Urine was most common specimen accounting for 42% followed by pus (34%), blood (9%), ear swab (5%), body fluid (4%), sputum and catheter tip (3%each). The clinical samples from indoor patients yielded highest percentage of NFGNB (38%) followed by ICU patients (36%) and outdoor patients (26%). Among the NFGNB isolated *Pseudomonas aeruginosa* (51%) was the most common followed by *Acinetobacter baumannii* (22%), *Pseudomonas* spp

(19%), *Acinetobacter* spp, *Stenotrophomonas maltophilia*, *Burkholderia cepacia* (2% each), *Ralstonia* spp & *Sphingobacterium* spp (1%). Non fermenters were highly sensitive to Imipenem accounting for 91.5% followed by Piperacillin-tazobactam (71.5%), cefoperazone sulbactam (67.7%) & Amikacin (55.6%) on an average.

Conclusion: NFGNB considered being contaminants in the past have now emerged as important health care associated infections. In our setting Imipenem can be used for the preliminary treatment of infections caused by nonfermenters. As these organisms are important opportunistic and nosocomial pathogens causing infections in immunocompromised patients, better infection control policies in our settings and its implementation is a must.

Keywords: Nonfermenting Gram Negative Bacilli, *P. aeruginosa*, *Acinetobacter baumannii*, *Pseudomonas* spp, *Acinetobacter* spp., Imipenem.


*Correspondence to:

Dr. Aparna Aparajita,
Junior Resident,
Department of Microbiology,
RIMS, Bariatu, Ranchi, Jharkhand.

Article History:

Received: 20-03-2019, Revised: 16-04-2019, Accepted: 15-05-2019

Access this article online

Website: www.ijmrp.com	Quick Response code 
DOI: 10.21276/ijmrp.2019.5.3.022	

INTRODUCTION

The group of organisms referred to as Nonfermenting gram negative bacilli (NFGNB) are taxonomically diverse group of aerobic, non sporing bacilli that either do not utilize glucose as a source of energy or utilize it oxidatively.¹ They occur in the environment as saprophytes, previously considered as contaminants or commensals.^{2,3}

Recent literature suggests that these organisms are associated with certain life threatening infections such as septicaemia, pneumonia, urinary tract infections, meningitis, surgical site

infections, ventilator associated pneumonia, wound infection, osteomyelitis etc.³ NFGNB account for around 15% of all bacterial isolates in a clinical microbiology lab of a hospital setting.⁴ The emergence of NFGNB as important health care associated pathogens can be attributed to indiscriminate and injudicious use of broad spectrum antibiotics as these organisms show resistance to drugs routinely administered in clinical practice in health care settings.⁵ NFGNB have innate resistance to certain antibiotics and are also known to produce extended spectrum beta lactamases



(ESBL) and metallo beta lactamases (MBL).⁶ There is paucity of literature from our area on NFGNB, their presence in various clinical samples and their antibiotic sensitivity. Therefore, this study was undertaken to know the prevalence of these organisms in all the clinical samples along with their clinical significance. As these groups of organisms are intrinsically resistant to many antibiotics and have also developed acquired resistance to many drugs it is imperative to know their antibiotic sensitivity profile so as to fulfill the goals of antibiotic stewardship and help in reducing the cost of treatment on both patients as well as our health care settings.

MATERIALS AND METHODS

The study was a cross-sectional study done in the bacteriology section of Department of Microbiology, RIMS, Ranchi for a period of 6 months from February 2017- July 2017. All the clinical samples received at the bacteriology section were inoculated on blood agar, Mac Conkey Agar, CLED Agar and incubated at 37° C for 48hrs. All the isolates that were nonlactose fermenting and showed alkaline/ no change (K/NC) reaction on Triple Sugar Iron

(TSI) Agar slant were provisionally considered as NFGNB and were further identified using the standard protocol for identification. The tests performed were Gram stain for morphology, hanging drop for motility, oxidase test, catalase test, citrate utilization, oxidative-fermentative test (Hugh-Leifson medium) for glucose, lactose, sucrose, maltose, mannitol and xylose, gelatin liquefaction, lysine ornithine decarboxylation, arginine dihydrolase test, growth at 42°C and 44°C.

Antimicrobial sensitivity was performed using Kirby-Bauer disc diffusion method on Mueller-Hinton Agar using commercially available antimicrobial discs (Hi-media). The different antibiotics used were Ampicillin (10µg), Ciprofloxacin (5µg), cotrimoxazole (1.25/23.75µg), Cefotaxime (30µg), cefpodoxime (10µg), Gentamicin (10µg), Levofloxacin (5µg), Nalidixic Acid (30µg), Nitrofurantoin (300µg), Amoxicillin (25µg), Netilmycin (30µg), Amikacin (30µg), Ampicillin-sulbactam (10/30µg), Imipenem (10), Piperacillin- tazobactam (100/10µg). The results were interpreted using Clinical and Laboratory Standard Institute guidelines.⁷ Controls used were *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853.








Table 1: Non fermenters isolated from different clinical samples

Samples	PA	PS	AB	AS	BC	SM	RS	SS	Total
Urine	51	13	24	1	-	-	1	1	91
Pus	43	10	13	1	1	3	2	1	74
Ear swab	4	6	1	-	-	-	-	-	11
Sputum	2	2	2	-	-	-	-	-	6
Body fluid	3	3	2	-	-	-	-	-	8
Blood	5	4	5	2	3	2	-	-	21
Catheter tips	2	2	1	-	-	-	-	1	6
Total	110	40	48	4	4	5	3	3	217

PA: *P. aeruginosa*; PS: *Pseudomonas* spp.; AB: *Acinetobacter baumannii*; AS: *Acineto. Spp*; BC: *Burkholderia cepacia*; SM: *Stenotrophomonas maltophilia*; RS: *Ralstonia* spp; SS: *Sphingobacterium* spp.

Table 2: Antibiotic sensitivity of non fermenting Gram negative Bacilli

Antibiotics (μ g)	AB		AS		SM		BC		SS		RS	
	S%	R%	S%	R%	S%	R%	S%	R%	S%	R%	S%	R%
Imipenem (10)	77	23	50	50	100	0	100	0	100	0	100	0
Amikacin (30)	43.7	36.2	25	75	50	50	50	50	33.3	66.7	0	100
Cefo+ sul (75/30)	33.3	66.7	25	75	100	0	75	25	33.3	66.7	0	100
Ampi+sul (10/10)	14.5	85.5	0	100	25	75	25	75	33.3	66.7	0	100
Pipera+tazo (100/10)	66.6	33.4	50	50	60	40	50	50	100	0	66.7	33.3
Cotrim (1.25/23.75)	29.1	70.8	75	25	60	40	50	50	66.7	33.3	100	0
Levo (5)	18.7	81.2	25	75	50	50	0	100	33.3	66.7	66.7	33.3

AB; *Acinetobacter baumannii*; AS: *Acineto. Spp*; BC: *Burkholderia cepacia*; SM: *Stenotrophomonas maltophilia*; RS: *Ralstonia* spp; SS: *Sphingobacterium* spp.

Table 3: Antibiotic sensitivity of *Pseudomonas aeruginosa* and *Pseudomonas* spp.

Antibiotics (μ g)	<i>Pseudomonas aeruginosa</i>		<i>Pseudomonas</i> spp	
	S%	R%	S%	R%
Imipenem (10)	88.1	11.9	85	15
Amikacin (10)	44.5	55.5	57.5	42.5
Cefopera+ sulbac (75/30)	74.5	25.5	26.3	73.7
Ampi+ sulbactam (10/30)	30.9	69.1	11.8	88.2
Pipe+ tazo (100/10)	53.6	46.4	23.6	76.4
Cotrimoxazole (1.25+23.75)	35.4	64.6	15.4	84.6
Levofloxacin (5)	70	30	22.7	77.3

RESULTS

A total of 3581 samples were received out of which 2246 were culture positive and 217 were identified as NFGNB. The isolation rate of NFGNB was 9.6%. Number of males was 121 and that of females was 96 the ratio being 1.26 as depicted in Fig 1. The clinical samples from indoor patients yielded highest percentage of NFGNB (38%) followed by ICU patients (36%) and outdoor patients (26%). (Fig 2)

Analysed by specimen NFGNB were isolated from 91 urine, 74 pus, 11 ear swab, 6 sputum, 8 body fluids, 21 blood culture and 6 catheter tip samples. Urine was most common specimen accounting for 42% followed by pus (34%), blood (9%), ear swab (5%), body fluid (4%), sputum and catheter tip (3%each). (Table 1,

Fig 3) Among the NFGNB isolated *Pseudomonas aeruginosa* (51%) was the most common followed by *Acinetobacter baumannii* (22%), *Pseudomonas* spp (19%), *Acinetobacter* spp, *Stenotrophomonas maltophilia*, *Burkholderia cepacia* (2% each), *Ralstonia* spp. and *Sphingobacterium* spp.(1%) each. (Table 1, Fig 4)

The antibiotic sensitivity pattern of Non fermenters showed them to be highly sensitive to Imipenem accounting for 91.5% on an average followed by Piperacillin-tazobactam (71.5%), cefoperazone-sulbactam (67.7%) & Amikacin (55.6%) on an average. Most of the organisms showed resistance to Cefotaxime and Cotrimoxazole. (Table 2, 3, Fig 5)

DISCUSSION

Previously considered as commensals or contaminants, these groups of organisms have shown themselves to be of pathogenic potential as they have been frequently isolated from clinical samples from hospitalised and immunocompromised patients. They have gained importance as causative agents of nosocomial infections having intrinsic as well as acquired resistance to different classes of drugs used frequently in clinical practice by the medical practitioners.

Out of 3581 samples received in our bacteriology section 217 were identified as NFGNB so that the isolation rate in our set up was 9.6% which is different from studies done by Bruno et al.⁸, Malini et al.⁹, Benachinmardi et al.¹⁰ where the isolation rate was 2.18%, 3.58% and 4.5% respectively. Our study had isolation rates parallel to studies done by Samanta et al.¹¹ where the isolation rate was 10%. Eltahawy and Khalaf¹², Vijaya et al.² and Sidhu et al.¹³ have reported higher isolation rates of 16%, 21.8% and 45.9% respectively.

Urine was the most common sample from which NFGNB were isolated. 91 urine samples (42%) yielded NFGNB followed by pus samples which accounted for 74 (34%). The common organisms isolated from urine samples were *Pseudomonas aeruginosa* (51), *Acinetobacter baumannii* (24), *Pseudomonas* spp. (13). Those isolated from pus were *Pseudomonas aeruginosa* (43) *Acinetobacter baumannii* (13) *Pseudomonas* spp (10). *Acinetobacter baumannii* (5) and *Pseudomonas aeruginosa* (5) were frequently isolated from blood cultures.

Maximum number of isolates from our study were isolated from urine samples (42%) which is different from that observed in other studies where most of the isolates were from pus samples.^{5,6,14,15} NFGNB isolated from indoor patients was more than the outdoor patients which is in concordance to other studies done by Benachinmardi et al.¹⁰, Jayanti and Jeya¹⁶ and Juyal.³ *Pseudomonas aeruginosa* and *Acinetobacter baumannii* were the most common NFGNB isolated from clinical samples which is similar to studies done by others.⁹

Nosocomial pathogens show resistance pattern which varies world-wide, from country to country and within the same country at different time periods.¹⁷

In our study most of the NFGNB were sensitive to Imipenem followed by Piperacillin-tazobactam, cefoperazone-sulbactam, and Amikacin. *Pseudomonas aeruginosa* was 88.1% and *Pseudomonas* spp was 85% sensitive to Imipenem. *Burkholderia*, *Sphingotrophomonas*, *Ralstonia* were 100% sensitive to Imipenem. *Acinetobacter baumannii* was 77.5% sensitive to Imipenem. Imipenem was followed by piperacillin-tazobactam sensitivity wherein *Sphingobacterium* was 100% sensitive, *Pseudomonas aeruginosa* was sensitive 53.6% and *Acinetobacter baumannii* showed 66.6% sensitivity to PTZ.

Pseudomonas spp showed good sensitivity to cefoperazone-sulbactam (74.5%). Levofloxacin showed good sensitivity to *Pseudomonas aeruginosa* (70%). The sensitivity shown by Cotrimoxazole showed to *Stenotrophomonas* (60%) and *Sphingobacterium* (66.6%).

Other studies showed good sensitivity to amikacin^{2,5,9} whereas some other studies showed 60-70% resistance to amikacin and ciprofloxacin.^{3,17,18} Imipenem showed very good sensitivity as in other studies by Malini et al.⁹, Gupta¹⁹, Gladstone et al.²⁰,Hodiwala.²¹

CONCLUSION

Pseudomonas aeruginosa and *Acinetobacter baumannii* were the most common NFGNB isolated from various clinical samples in our study. They were associated with a number of infections like urinary tract infection, wound infection, surgical site infection, ventilator associated pneumonia, septicaemia and respiratory tract infections. *Pseudomonas aeruginosa* shows good sensitivity to Imipenem, Piperacillin-tazobactam and cefoperazone-sulbactam. *Acinetobacter* also showed good sensitivity to Imipenem but not to other drugs due to resistance to other drugs. Most of the NFGNB have shown good response to Imipenem thereby making it the drug of choice in our healthcare setting. But they were resistant to other broad spectrum antibiotics like cefotaxime and cefpodoxime. Also amikacin that has proved to be a good choice against these NFGNB is mostly resistant in our setting. Therefore it becomes necessary to keep an eye on the sensitivity pattern to guide the clinician for better patient care and management. As they are nosocomial pathogens they survive in hospital environment and are responsible for propagation of infection, therefore formulating infection control policies and following antibiotic stewardship along with its implementation is a must in our healthcare setting to prevent the emergence of drug resistant strains and their spread. Its high time to conserve our resources and our antibiotics to combat the growing power of drug resistant organisms before they outreach complete resistance.

REFERENCES

1. Winn W Jr, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, et al., editors. Nonfermenting Gram negative bacilli. In: Koneman's color Atlas and textbook of Diagnostic Microbiology. 6th ed. USA: Lippincott Williams and Wilkins Company; 2006. p. 305-916.
2. Vijaya D, Kamala, Bavani S, Veena M. Prevalence of nonfermenters in clinical specimens. Indian J Med Sci 2000; 54:87-91.
3. Juyal D, Prakash R, Shankarnarayan S A, Sharma M, Negi V, et al. Prevalence of non-fermenting Gram negative bacilli and their in vitro susceptibility pattern in a tertiary care hospital of Uttarakhand: A study from foothills of Himalayas. Saudi J Health Sci 2013; 2:108-12.
4. Rubin SJ, Granato PA, Wasilaukas BL. Glucose non fermenting Gram negative bacteria. In: Lennette EH, Balows A, Hausser WJ Jr, Shadomy HJ, editors. Manual of Clinical Microbiology. 4th ed. Washington, D.C: American Society for Microbiology; 1895. pp.330-49.
5. Gokhale S, Metgud SC. Characterization and antibiotic sensitivity pattern of nonfermenting Gram negative bacilli from various clinical samples in a tertiary care hospital. Belgaum J Pharm Biomed Sci 2012;17:1-5.
6. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogen in seriously ill patients: Geographical patterns, Epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001;32:104-13.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement, CLSI Document M100-S23. Wayne PA: Clinical and Laboratory Standards Institute; 2013.

8. Bruno D, Nishino MK, Priore WN, Remus PR, do Carmo AA, Stefanello VB, et al. Prevalence of Gram negative nonfermenters patients in Porto Alegre RS. *Jornal Brasileiro de Patologia e Medicina Laboratorial* 2011;47:529-34.
9. Malini A, Deepa EK, Gokul BN, Prasad SR. Nonfermenting gramnegative bacilli infections in a tertiary care hospital in Kolar, Karnataka. *J Lab Physicians* 2009;1:62-6.
10. Benachinmardi, Kirtilaxmi K, Padmavathy M, Malini J, Naveneeth B.V. Prevalence of non-fermenting Gram negative bacilli and their in vitro susceptibility pattern at a tertiary care teaching hospital. *J Sci Soc* 20120. 4;41:162-6.
11. Samanta P, Gautam V, Thapar R, Ray P. Emerging resistance of non-fermenting gram negative bacilli in a tertiary care centre. *Indian J Pathol Microbiol* 2011;54:666-7.
12. Eltahawy AT, Khalaf RM. Antibiotic resistance among gramnegative non fermentative bacteria at a teaching hospital in Saudi Arabia. *J Chemother* 2001;13:260-4.
13. Sidhu S, Arora U, Devi P. Prevalence of nonfermentative gram negative bacilli in seriously ill patients with bacteraemia. *JK Science* 2010; 12: 168-71.
14. Madhta L, Bhat KG. Nonfermenting Gram negative bacilli infections in hospitalized children. *Indian Assoc Biomed Sci* 1999;19:99-102.
15. Veenakumari HB, Nagarathna S, Chandramuki A. Antimicrobial resistance pattern among aerobic Gram negative bacilli of lower respiratory tract specimens of intensive care unit patients in a neurocentre. *Indian J Chest Dis Allied Sci* 2007;49:19-22.
16. Jayanthi S, Jeya M. Clinical distribution and antibiotic resistance pattern of nonfermenting Gram negative bacilli. *Int J Pharm Bio Sci* 2012;3:487-94.
17. Prashanth K, Badrinath S. In vitro susceptibility pattern of acinetobacter species to commonly used cephalosporins, quinolones, and aminoglycosides. *Indian J Med Microbiol* 2004;22:97-103.
18. Taneja N, Maharwal S, Sharma M. Imipenem resistance in nonfermenters causing nosocomial urinary tract infections. *Indian J Med Sci* 2003;57:294-9.
19. Gupta V, Chhina D, Kaur A. Incidence of metallo-beta-lactamase (MBL) producing nonfermenters isolated from respiratory samples in ICU patients. *Int J Pharm Bio Sci* 2013;4:580-5.
20. Gladstone P, Rajendran P, Brahmadathan KN. Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units. *Indian J Med Microbiol* 2005;23:189-91.
21. Hodiwala (Bhesania) A, Dhoke R, Urhekar AD. Incidence of metallo-beta-lactamase producing *Pseudomonas*, *Acinetobacter* & enterobacterial isolates in hospitalised patients. *Int J Pharm Bio Sci* 2013;3:79-83.

Source of Support: Nil.

Conflict of Interest: None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article as: Ashok Kumar Sharma, A. Aparajita, Manoj Kumar, Amber Prasad. Prevalence of Non Fermenting Gram Negative Bacilli with Their in vitro Antibiotic Sensitivity Profile in RIMS, Ranchi. *Int J Med Res Prof.* 2019 May; 5(3):105-10. DOI:10.21276/ijmrp.2019.5.3.022